1. Introduction {#sec1}
===============

Cardiovascular diseases are a leading cause of death in humans. Anoxia/reoxygenation (A/R) injury refers to a phenomenon in which ischemia/reperfusion (I/R) myocardial tissues aggravate the injury to myocardial structures and functions \[[@B1]\], which can lead to arrhythmia, heart hypofunction, cardiomyocyte apoptosis, and other disorders \[[@B2]\]. It is widely accepted that mitochondrial Ca^2+^ overload and increased reactive oxygen species (ROS) can result in mitochondrial dysfunction, such as loss of mitochondrial membrane potential (MMP), opening of the mitochondrial permeability transition pore (mPTP), activities of caspase-3, and release of cytochrome c, which can ultimately lead to cardiomyocyte apoptosis.

Antiapoptotic multidomain proteins (Bcl-2 and Bcl-xL) mainly reside in mitochondria, protecting against the opening of the mPTP, one of the rate-limiting events of apoptosis induction \[[@B3]\]. Additionally, the caspase family of cysteine aspartic proteases plays an important role at the initiation and finish of cell apoptosis and represents the executors of cellular apoptosis. For instance, caspase-3 is the primary activator of apoptotic DNA fragmentation \[[@B4]\]. Some reports showed that proapoptotic signals cytochrome c trigger caspase cascade amplification reaction, which lead to the cleavage of a set of proteins \[[@B5], [@B6]\]. It is worth noting that researchers find that antiapoptotic members of Bcl-2 family act primarily to preserve mitochondrial integrity by suppressing the release of cytochrome c \[[@B7]\], protecting the cell from disassembly. Therefore, many cardioprotective methods, such as ischemic precondition or postcondition, as well as agents known to have cardioprotective effects converge on the reduction of Ca^2+^ overload and/or ROS generation \[[@B8]\] and/or promotion of antiapoptosis of antiapoptotic proteins.

Sirtuins, a family of NAD^+^-dependent protein deacetylases, regulate biological function through deacetylation of many target proteins including proteins regulating antiaging genes \[[@B9]\]. SIRT1, a mammalian ortholog of silent information regulator 2 (Sir2) family, is the founding member of sirtuins. SIRT1 can deacetylate a variety of substrates and is involved in a broad range of physiological functions, including control of gene expression, cell cycle regulation, apoptosis, DNA repair, metabolism, oxidative stress response, and aging \[[@B10]--[@B14]\]. It provides protection against apoptosis and plays an essential role in mediating the survival of cardiomyocytes under stress in vitro. For example, pharmacological studies have shown that SIRT1 overexpression protects cardiomyocytes from serum deprivation-induced death \[[@B15]\]. Conversely, reduced SIRT1 activity in cardiomyocytes contributes to their death during heart failure \[[@B16]\].

Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide, C~18~H~27~NO, Cap) is a naturally occurring alkaloid derived from plants of the genus *Capsicum*, better known as chili pepper. It has been shown that application of Cap significantly attenuates myocardial injury due to I/R in rats \[[@B17]--[@B19]\]. However, the mechanisms underlying these effects have not been elucidated. Therefore, the aims of the study were to test (1) whether SIRT1 was involved in the protective effects of Cap on cardiomyocytes against A/R-induced injury; (2) whether the involvement of SIRT1 in the cardioprotection of Cap was through decrease in ROS generation and oxidative injury induced by A/R; (3) whether preservation of mitochondria by SIRT1 was involved in the cardioprotection of Cap on cardiomyocytes against A/R-induced injury.

2. Materials and Methods {#sec2}
========================

2.1. Reagents {#sec2.1}
-------------

Capsaicin (Cap, purity \> 98%) was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Sirtinol, the specific inhibitor of SIRT1, was purchased from Selleckchem (S2804). Anti-SIRT1 antibody was purchased from Abcam (ab32441, USA). Anti-caspase-3, anti-Bcl2, anti-cytochrome c, and anti-Cox4 were purchased from Cell Signaling Technology (Beverly, MA). Anti-*β*-actin was purchased from the Jiancheng Bioengineering Institute of Nanjing. The horseradish peroxidase-labeled IgG secondary antibodies were purchased from Cell Signaling Technology (Beverly, MA).

2.2. Cell Culture and Experimental Design {#sec2.2}
-----------------------------------------

All experimental protocols and procedures were carried out following the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication number 85-23, revised 1996) and approved by the Ethics Committee of Nanchang University (number 2015-0036). Cardiomyocytes from 2-day-old Sprague Dawley rats were prepared as previously described \[[@B20]\]. Briefly, the ventricles were digested with pancreatin (1 mg/ml) in the D-Hanks\' balanced salt solution (Na~2~HPO~4~·12 H~2~O 0.37 g, NaHCO~3~ 0.35 g, NaCl 8.00 g, KCl 0.40 g, and KH~2~PO~4~ 0.06 g). The cells were harvested after centrifugation (5 min, 60*g*), resuspended in the plating medium (85% DMEM, 15% FCS, and 100 U/ml of penicillin and streptomycin), and preplated on to the 60 mm Primaria culture dishes precoated with 1% gelatin (37°C, 30 min) to remove nonmyocytes. The nonadherent cardiomyocytes were plated on the gelatin-coated 60 mm Primaria culture dishes at 1 × 10^6^ cells per dish. After 18 h, the cardiomyocytes were washed and cultured in the serum-free maintenance medium (80% DMEM, 20% M199, and 100 U/ml of penicillin and streptomycin) for the duration of the experiments.

Following a 2-day culture, the cardiomyocytes were exposed to anoxia induced by adding fresh anoxia medium (NaH~2~PO~4~ 0.9 mM, NaHCO~3~ 6.0 mM, KCl 10.0 mM, NaCl 98.5 mM, CaCl~2~ 1.8 mM, MgSO~4~ 1.2 mM, sodium lactate 40 mM, and HEPES 20 mM at pH 6.8, 37°C) and then incubated in a chamber with an atmosphere of 95% N~2~ and 5% CO~2~ for 4 h. Following 4 h of anoxia, the anoxia medium was removed from the cells and the reoxygenation medium (KCl 5.0 mM, NaCl 129.5 mM, CaCl~2~ 1.8 mM, NaH~2~PO~4~ 0.9 mM, NaHCO~3~ 20 mM, MgSO~4~ 1.2 mM, glucose 5.5 mM, and HEPES 20 mM at pH 7.4, 37°C) was added. Then cells were incubated in an incubator with an atmosphere of 5% CO~2~ for 2 h. In the control normoxic experiments, the cells were incubated with fresh culture growth medium in an incubator with an atmosphere of 5% CO~2~ for 6 h. The cells were cultured with Cap (from 10 *μ*M to 40 *μ*M) or Cap (20 *μ*M) plus Sirtinol (60 *μ*M, Selleckchem, USA. Some researches have reported that the IC50 of human SIRT1 is 131 *μ*M and that furthermore 60 *μ*M, this dosage was confirmed in our preliminary experiments) 24 h prior to the experiment, respectively \[[@B21]\].

2.3. MTS Assay {#sec2.3}
--------------

A colorimetric MTS \[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium\] assay was used to investigate cell viability of the cardiomyocytes after A/R. MTS (Promega, USA) is a pale yellow substrate that produces a dark blue formazan product, which directly dissociates in medium when incubated with living cells. The primary cardiomyocytes were planted in 96-well plates at a concentration of 1 × 10^4^ cells/well. After induction of A/R, the cells were incubated at 37°C with 20 *μ*l MTS (5 mg/ml) in 100 *μ*l of the medium for 4 h. After 4 h, the absorbance of each well was measured at a wavelength of 490 nm by a microplate reader (Bio-Rad 680, USA). The results were expressed as a percentage of the control.

2.4. Biochemical Parameters {#sec2.4}
---------------------------

The culture media after 6 h of cell culture or cell lysate supernatants for each group were collected to evaluate the activities of creatine phosphate kinase (CPK) and lactate dehydrogenase (LDH) using commercially available assay kits (Jiancheng, China) according to the manufacturers\' instructions.

2.5. Western Blot Assay {#sec2.5}
-----------------------

Harvested cells were lysed with radio immunoprecipitation (RIPA, Beyotime, China) and incubated at 4°C for 2 h. The extracts were later centrifuged at 15, 294 ×g at 4°C for 15 min to remove any insoluble materials. Equal amounts of total protein (20 *μ*g) were diluted in the sample buffer containing 100 mM dithiothreitol, and the samples were heated at 98°C for 5 min and then subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis in a gel apparatus (Bio-Rad, USA). Subsequently, the proteins were transferred onto polyvinylidene fluoride membranes. The membranes were then blocked with 5% skim milk in the TBS-T (a mixture of Tris-buffered saline and 0.2% Tween-20) for 2 h and then incubated with antibodies against SIRT1, Bcl-2, cytochrome c, and caspase-3 diluted at 1 : 500 in the TBS-T, and the membranes were continuously shaken at room temperature for 1 h, followed by washing with the TBS-T (20 min per time) and incubation with horseradish peroxidase-conjugated secondary antibody (1 : 2000 dilution) for 1 h. Next, the membranes were washed 3 times, 10 min each in the TBS-T. For detection, the membranes were saturated with an enhanced chemiluminescence mixture for 1 min and viewed by autography using preflashed X-ray film (Fujifilm, Tokyo) for 300 s. The bands were analyzed with densitometric scanning using Quantity One software.

2.6. Measurement of Intracellular ROS {#sec2.6}
-------------------------------------

Dichlorodihydrofluorescein diacetate (DCFH-DA) was membrane-permeable dye and used to determine whether a reduction in ROS generation that an underlying mechanism of cardioprotective effects of Cap. DCFH-DA was converted by intracellular esterases into 2′,7′-dichlorodihydrofluorescein, which was then oxidized by ROS into highly fluorescent 2′,7′-dichlorofluorescein. The assay was performed according to the protocol provided by the manufacturer. Briefly, the cells were washed twice with ice-cold phosphate-buffered saline (PBS) and incubated in the DMEM solution containing 10 *μ*M DCFH-DA (Invitrogen, USA). Next, the samples were centrifuged at 800*g* for 5 min and washed twice with the ice-cold PBS, and the fluorescence intensity of each group was determined using a flow cytometer (Becton Dickinson, USA) at excitation and emission wavelengths of 485 and 528 nm, respectively.

2.7. Assessment of Mitochondrial Membrane Potential (MMP) {#sec2.7}
---------------------------------------------------------

MMP was assessed using the fluorescent dye JC-1 (Invitrogen, USA). Suspension of the cardiomyocytes was incubated with JC-1 (200 *μ*M) for 20 min at 37°C followed by washing twice with PBS to remove remaining reagents. The fluorescence was then measured by a flow cytometer (Becton Dickinson, USA) with first at excitation and emission wavelengths (ex/em) of 530 and 580 nm (red) and then at ex/em of 485/530 nm (green), respectively. JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimida-zolo carbocyanine iodide) is a lipophilic, cationic dye that can selectively enter mitochondria and reversibly change color from green to red when MMP increases. The ratio of red to green fluorescence intensity of cells reflects the level of MMP.

2.8. Preparation of Mitochondrial and Cytosolic Fractions {#sec2.8}
---------------------------------------------------------

Mitochondrial and cytosolic fractions of cells were prepared using a mitochondrial/cytosolic fractionation kit (Qiagen, Germany). The cardiomyocytes with or without undergoing A/R were harvested by centrifugation at 500 ×g for 10 min and washed twice with an ice-cold sodium chloride solution. Afterwards, the cells were resuspended with 1 ml of ice-cold lysis buffer containing a protease inhibitor. After being incubated for 10 min at 4°C on an end-over-end shaker, the lysate was centrifuged at 1000 ×g for 10 min. The supernatant was harvested and designated as the cytosolic fractions. The cell pellet was resuspended with 1.5 ml of ice-cold disruption buffer containing a protease inhibitor and homogenized using a Kontes Dounce tissue grinder on ice. Homogenization was centrifuged at 1000 ×g for 10 min at 4°C, and the supernatant was collected. Then the collected supernatant was centrifuged at 6000 ×g for 10 min at 4°C. The supernatant was removed, and the pellet was washed with 1 ml Mitochondria Storage Buffer. Then, the lysate was centrifuged at 6000 ×g for 20 min at 4°C and the mitochondrial pellet was resuspended in an appropriate buffer and designated as mitochondrial fractions.

2.9. Opening of mPTP {#sec2.9}
--------------------

The isolated mitochondrial fractions were then suspended with swelling buffer (KCl 120 mM, Tris-HCl 10 mM, MOPS 20 mM, and KH~2~PO~4~ 5 mM) and added to a 96-well microtiter plate. The addition of 40 *μ*l of CaCl~2~ solution (200 nM) to each well acted as a stimulant of the opening of mPTP and resulted in a stable decline in mitochondrial optical density. The absorbance at 520 nm was measured every minute until stable values were observed. The changes in absorbance were used to measure the extent of mPTP opening.

2.10. Assessment of Caspase-3 Activity {#sec2.10}
--------------------------------------

Ac-DEVD-рNA (acetyl-Asp-Glu-Val-Asp p-nitroanilide) could be catalyzed by caspase-3 to produce a yellow substance pNA (p-nitroaniline), which has the highest absorbance at 405 nm to detect the activity of caspase-3. The assay was carried out as the protocol provided by the manufacturer of the caspase-3 activity assay kit (Beyotime, China). In brief, the cells were collected and washed once by PBS. The supernatant was removed, and the lysis buffer was added to the cells at the ratio of 100 *μ*l for 2 × 10^7^ cells on ice for 15 min then centrifuged at 16000 ×g for 15 min. The supernatant was transferred to a cold tube, and the detection buffer and Ac-DEVD-рNA were added. The mixture was incubated at 37°C for 2 h to detect the absorbance at a wavelength of 405 nm.

2.11. Flow Cytometry Assay of Cardiomyocyte Apoptosis {#sec2.11}
-----------------------------------------------------

Assessment of apoptosis was done by using flow cytometry with an Annexin V-FITC apoptosis detection kit according to the manufacturer\'s protocol. The cardiomyocytes were washed twice with cold PBS and then resuspended in a buffer solution to a final concentration of 1 × 10^6^ cells/ml. Annexin V-FITC (5 *μ*l) and PI (5 *μ*l) were added to the cells, which were resuspended in 500 *μ*l of 1x binding buffer. The cells were gently vortexed, incubated in the dark at room temperature for 15 min, and analyzed on a flow cytometry (ex488 nm and em578 nm, Becton Dickinson, USA) within 1 h. At least 10,000 cells were analyzed in each group, and the analysis of apoptotic cells was performed using the Cell Quest software (BD Biosciences, CA, USA).

2.12. TUNEL Assay of Cardiomyocyte Apoptosis {#sec2.12}
--------------------------------------------

Cardiomyocyte apoptosis was detected by the terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) assay. The cardiomyocytes were plated on glass Lab-Tek Chamber slides (Sigma), washed with PBS, then fixed with 1% paraformaldehyde for 10 min. The cardiomyocytes were then fixed in precooled ethanol-acetic acid (2 : 1) for an additional 5 min at −20°C. After washing with PBS, the cells were incubated with TUNEL reaction buffer at 37°C in a humidified chamber for 1 hour. Cells were treated with DNase I (1.0 mg/ml, Sigma) for 10 min, so that nickel could be introduced into genomic DNA, as a positive control. Brown-colored cells represent apoptotic cells in each glass slide under the high magnification (×400) microscope (Olympus, Tokyo, Japan). The apoptotic rate of cardiomyocyte was measured by DNA nickel-end labeling, and the number of brown cells nuclei in 1000 cells was counted by repeated plate method.

2.13. Statistical Analysis {#sec2.13}
--------------------------

All values were expressed as mean ± SEM. One-way ANOVA was applied to test the significance of differences in the biochemical data across groups, followed by post hoc testing for individual differences. The results were considered significant at a value of *P* \< 0.05. For each assessment, at least six independent trials were performed.

3. Results {#sec3}
==========

3.1. Cap Increased Viabilities of the Cardiomyocytes after Undergoing A/R {#sec3.1}
-------------------------------------------------------------------------

Cell viabilities with or without undergoing A/R were shown in [Figure 1(a)](#fig1){ref-type="fig"} and Figure [S1](http://downloads.hindawi.com/journals/omcl/2017/1035702.f1.doc)A of the section of Supplementary Materials. Compared with the control group, A/R significantly decreased cell viability compared with A/R group. Cap significantly increased the cell viabilities in a dose-dependent manner, and the optimal concentration of Cap was 20 *μ*M (*P* \< 0.01 versus the A/R group). When Cap concentration reached 40 *μ*M, the cell viabilities started to decrease that indicates Cap was toxic to the cardiomyocytes when the concentration of Cap was higher than the optimal concentration. Thus, Cap concentration of 20 *μ*M was chosen for subsequent experiments. The A/R group pretreated with 20 *μ*M Cap and 60 *μ*M sirtinol demonstrated lower cell viabilities than the Cap 20 *μ*M + A/R group (*P* \< 0.01). However, the cell viabilities did no change using Cap alone, sirtinol alone, and Cap + sirtinol compared with the control group (*P* \> 0.05), as well as using sirtinol + A/R compared with the A/R group (*P* \> 0.05).

The activities of LDH and CPK in the culture mediums after cell culture in A/R or normoxic medium were analyzed to evaluate the cell conditions. There was a significant increase in the activities of LDH and CPK in the A/R group compared with the control group (*P* \< 0.01), while Cap significantly decreased the activities of LDH and CPK compared with the A/R group (*P* \< 0.01, [Figure 1(b)](#fig1){ref-type="fig"}). Effects of Cap on the LDH and CPK activities were significantly blocked by coadministration of sirtinol (*P* \< 0.01). Similarly, the activities of LDH and CPK did not change using Cap alone, sirtinol alone, and Cap + sirtinol compared with the control group (*P* \> 0.05, Figure [S1](http://downloads.hindawi.com/journals/omcl/2017/1035702.f1.doc)B), as well as using sirtinol + A/R compared with the A/R group (*P* \> 0.05, Figure [S1](http://downloads.hindawi.com/journals/omcl/2017/1035702.f1.doc)B).

3.2. Cap Upregulated SIRT1 Expression in the Cardiomyocytes following A/R {#sec3.2}
-------------------------------------------------------------------------

The effects of Cap on the expression of SIRT1 on the cardiomyocytes following A/R evaluated by Western blot assay were shown in [Figure 2](#fig2){ref-type="fig"} and Figure [S2](http://downloads.hindawi.com/journals/omcl/2017/1035702.f1.doc) of the section of Supplementary Materials. Compared with the control group, A/R significantly downregulated the expression of SIRT1 (*P* \< 0.01), regardless of whether with or without sirtinol. Pretreatment with Cap (20 *μ*M) significantly upregulated the expression of SIRT1 (*P* \< 0.01), regardless of whether using Cap alone or Cap + sirtinol. The A/R group pretreated with 20 *μ*M Cap and 60 *μ*M sirtinol demonstrated lower expression of SIRT1 protein than the Cap 20 *μ*M + A/R group (*P* \< 0.01).

3.3. Cap Decreased ROS Generation {#sec3.3}
---------------------------------

The ROS levels in the cardiomyocytes examined by measuring DCF fluorescence intensity are shown in [Figure 3](#fig3){ref-type="fig"}. The peak of ROS levels was moved to the right markedly, which indicated an obvious increase of ROS generation in the A/R group compared with the control group. Cap pretreatment caused a significant shift of the peak of ROS levels to the left ([Figure 3(a)](#fig3){ref-type="fig"}, *P* \< 0.01), which indicated a significant decrease in the ROS generation compared with the A/R group ([Figure 3(b)](#fig3){ref-type="fig"}, *P* \< 0.01). The peak of ROS in the cardiomyocytes induced by A/R in the group pretreated with Cap and sirtinol was shifted to the right compared with the Cap group ([Figure 3(a)](#fig3){ref-type="fig"}, *P* \< 0.01), which indicated a significantly more ROS generation than the Cap group ([Figure 3(b)](#fig3){ref-type="fig"}, *P* \< 0.01).

3.4. Cap Altered MMP in the Cardiomyocytes after Undergoing A/R {#sec3.4}
---------------------------------------------------------------

A loss of MMP is an early sign of apoptosis. In living cells, JC-1 accumulates in the mitochondrial matrix, where it emits a red fluorescence. In apoptotic and dead cells, the MMP is lost, and JC-1 only exists in its monomeric form, which emits a green fluorescence. [Figure 4](#fig4){ref-type="fig"} shows the effects of pretreatment with Cap (20 *μ*M) or Cap (20 *μ*M) with sirtinol (60 *μ*M) on changes in the MMP in the cardiomyocytes induced by A/R. The ratio of the fluorescence in the lower right quadrant and upper right quadrant was used to evaluate the level of MMP. In the A/R group, there was a decrease in the ratio of fluorescence intensity (*P* \< 0.01), indicating a loss of MMP. Pretreatment with Cap significantly prevented the loss of MMP induced by A/R (*P* \< 0.01). However, the MMP was significantly decreased in the group pretreated with both Cap and sirtinol compared with the group pretreated with Cap (*P* \< 0.01).

3.5. Cap Treatment Inhibited the Opening of mPTP in the Cardiomyocytes Induced by A/R {#sec3.5}
-------------------------------------------------------------------------------------

mPTP opening plays a major role of cell apoptosis caused by A/R. Ca^2+^-induced mitochondrial swelling assay was used to determine mPTP opening. As shown in [Figure 5](#fig5){ref-type="fig"}, the mPTP opening in the A/R group was significantly increased compared with the control group (*P* \< 0.01), while Cap-pretreated group had a significant inhibitor the mPTP opening compared with the A/R group (*P* \< 0.01). The mPTP opening increased again in the Cap-pretreated and sirtinol group (*P* \< 0.01).

3.6. Cap Treatment Inhibited the Release of Mitochondrial Cytochrome c into the Cytosol in Cardiomyocytes Undergoing A/R {#sec3.6}
------------------------------------------------------------------------------------------------------------------------

Mitochondrial dysfunction results the release of mitochondrial cytochrome c into the cytosol. Western blot revealed that A/R led to an accumulation of cytochrome c in the cytosol ([Figure 6](#fig6){ref-type="fig"}) but the observed cytochrome c in the cytosol was significantly reduced when the cells were pretreated with Cap before A/R treatment (*P* \< 0.01). However, the accumulation increased when sirtinol was used (*P* \< 0.01). These results indicate that Cap is protective against such dysfunction.

3.7. Cap Treatment Reduced the Activities of Caspase-3 and Effected the Expression of Bcl-2 and Caspase-3 in Cardiomyocytes Undergoing A/R {#sec3.7}
------------------------------------------------------------------------------------------------------------------------------------------

Caspase families are proved to play a central role in mediating various apoptotic responses. The cells were collected to evaluate the activity of caspase-3 after A/R treatment. As shown in [Figure 7](#fig7){ref-type="fig"}, the activities of caspase-3 in the A/R group was significantly increased compared with the control group (*P* \< 0.01), while the Cap-pretreated group had a significant inhibitor the activities of caspase-3 compared with the A/R group (*P* \< 0.01). The activities of caspase-3 increased again in the Cap-pretreated and sirtinol group (*P* \< 0.01).

Further, Bcl-2 and caspase-3 were examined by Western blot ([Figure 8](#fig8){ref-type="fig"}). The protein expression of cleaved caspase-3 in the A/R group was obviously increased compared with the control group (*P* \< 0.01). Bcl-2 in the A/R group was significantly decreased compared with the control group (*P* \< 0.01). In contrast, treatment with Cap partially reduced the increased amounts of cleaved caspase-3 and upregulated the expression of Bcl-2. However, the amount of cleaved caspase-3 was slightly increased by treatment with Cap and sirtinol. Bcl-2 showed the opposite trend (*P* \< 0.01).

3.8. Cap Treatment Inhibits the Cardiomyocyte Apoptosis Induced by A/R {#sec3.8}
----------------------------------------------------------------------

After A/R treatment, the cardiomyocytes were harvested for Annexin V/PI double staining and then analyzed using flow cytometer ([Figure 9](#fig9){ref-type="fig"}). These results showed that compared with the A/R-treated group, cell apoptosis in the Cap-preconditioned group was significantly reduced (*P* \< 0.01). However, the cells preconditioned with Cap and sirtinol and only sirtinol demonstrated a higher level of apoptosis compared with the cells preconditioned with Cap only (*P* \< 0.01).

Further, the apoptosis of the cardiomyocytes was assayed using TUNEL staining ([Figure 10](#fig10){ref-type="fig"}). In microscopy, the A/R group clearly promoted cardiomyocyte apoptosis when compared to that in the control group, as indicated by noticeable brown TUNEL-positive cardiomyocytes. Cap preconditioned in significant decreases in TUNEL-positive cardiomyocytes. However, the effects of Cap were weakened by sirtinol demonstrated. Consistent results were observed in terms of the percentage of apoptotic cardiomyocytes as determined by flow cytometry.

4. Discussion {#sec4}
=============

Due to high incidence of acute myocardial infarct, a major reason for myocardial cell injury, and prevalence of successful myocardial reperfusion therapy worldwide, A/R-induced myocardial injury has attracted extensive attention from researchers all over the world \[[@B22], [@B23]\]. Our data indicate that cardioprotective effects of Cap on A/R-induced injury may be mediated by SIRT1.

Infarction and reoxygenation injury are the leading reasons for myocardial cell injury and death in various cardiovascular diseases. A/R, as the infarction and reoxygenation experimental model, has been widely used. The pathogenesis of A/R injury is apparently multifactorial, including the following steps: (1) intracellular acidosis, loss of intracellular K^+^, and accumulation of metabolites; (2) intracellular Ca^2+^ overload, loss of gap junction expression/function, and irreversible cellular injury; (3) elevated levels of oxidative stress, progressive accumulation of ROS, and mitochondrial dysfunction \[[@B2]\]. During A/R, reintroduction of oxygen allows the generation of ATP. However, damage to the electron transport chain results in increased mitochondrial generation of ROS and various oxidative stress injuries. On the one hand, the altered ion homeostasis causes a rupture in the plasma membrane and cell death. On the other hand, ROS-mediated oxidative stress disturbs the balance between antiapoptotic (such as Bcl-2 and Bcl-XL) and proapoptotic (such as Bad, Bax, or Bid), resulting the cells more susceptible to apoptosis \[[@B24]\]. Pretreatment with Cap has been shown to produce preconditioning-like protection in the isolated perfused rat heart \[[@B25], [@B26]\].

The current study shows that A/R significantly increased the activities of LDH and CPK in the culture media and decreased cell viability and pretreatment with Cap significantly blocked the changes caused by A/R. This confirmed that Cap could protect cardiomyocytes from injury induced by A/R. Moreover, Western blot analysis has shown that SIRT1 expression significantly increased in the groups treated with Cap. Reducing ROS has been reported to reduce ischemic injury \[[@B8]\]. As shown in [Figure 3](#fig3){ref-type="fig"}, these results indicated that effects of Cap to reducing the generation of ROS and alleviating A/R-induced injury in the cardiomyocytes might be dependent on its ability to upregulate expression and activity of SIRT1. The breakdown of MMP is an early sign of apoptosis. During A/R, MMP disruption is mediated by the opening of mPTP in the inner mitochondrial membrane, resulting in matrix swelling, outer membrane rupture, and the release of apoptotic signalling molecules. In this study, we showed that Cap pretreatment could significantly preserve MMP stabilization, closed mPTP, and decreased the release of apoptotic-related factors. However, in the presence of sirtinol, all the protective effects of Cap were completely abolished (Figures [4](#fig4){ref-type="fig"}[](#fig5){ref-type="fig"}--[6](#fig6){ref-type="fig"}).

Bcl-2 family proteins function through different pathways in the regulation of cell apoptosis \[[@B27]\]. The intrinsic apoptotic pathway hinges on the balance between the activities of pro- and antiapoptotic members of the Bcl-2 family proteins, which act to regulate the permeability of the mitochondrial membrane \[[@B28]\]. It has been found that the high ratio of Bcl-2/Bax is associated with greater vulnerability to apoptotic activation \[[@B29], [@B30]\]. In addition, previous evidence indicated that higher expression of SIRT1 upregulated antiapoptotic proteins Bcl-2 and Bcl-xl, downregulated proapoptotic protein Bax, then increases cell viability in ischemia-reperfused myocardium \[[@B15]\]. Moreover, Bcl-2 and its homologs prevent mitochondrial membrane disruption and the release of cytochrome c and other proapoptotic factors. The current study shows that Cap pretreatment upregulated expression of Bcl-2 as well as reduced MMP and release of cytochrome c from the mitochondrial intermembrane space into the cytosol (Figures [4](#fig4){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and [8](#fig8){ref-type="fig"}).

The changes in levels of Bcl-2 family members may have a direct effect on mitochondrial membrane pore formation. This may lead to the activation of caspase-3 and the intrinsic apoptotic pathway. Moreover, many studies have confirmed that the overproduction of free radicals, intracellular calcium overload, mitochondrial injury, and inflammatory cell infiltration induced by A/R injury are related to the activation of apoptotic genes, such as caspase-3 \[[@B31], [@B32]\]. Caspase-3 responds to a variety of apoptosis-stimulating signals and acts as the ultimate enforcer of cellular apoptotic death. The activation of caspase-3 represents the irreversible phase of apoptosis \[[@B33]\]. Furthermore, numerous studies have shown that the MMP stimulates mPTP to open, resulting in the release of cytochrome c in to the cytoplasm, activation of the caspase pathway, and degradation of important intracellular proteins and consequently the induction of apoptosis \[[@B34], [@B35]\]. In the current study, the activities of caspase-3 increased by A/R were reduced by pretreatment with Cap. In the group pretreated with Cap and sirtinol, the activities of caspase-3 did not differ significantly from the A/R group. In addition, pretreatment with Cap prior to A/R decreased expression of the cleaved caspase-3. In the group pretreated with Cap and sirtinol, the level of cleaved caspase-3 did not differ significantly from the A/R group, suggesting that sirtinol blocks the effects of Cap. All of the data suggest that Cap may exert its protective effects on the cardiomyocytes via SIRT1.

Apoptosis plays an evident role in the A/R-induced injury to tissues and might be an important part of pathogenesis \[[@B36]\]. Moreover, SIRT1 might be the regulators of apoptosis, acetylated p53, Bax, and cleaved caspase-3 \[[@B37], [@B38]\] and regulates the acetylation level of transcription factor FOXO1 to affect apoptotic pathways in the heart \[[@B39], [@B40]\]. Thus, it is likely SIRT1-mediated deacetylation of active caspase-3, Bcl2, Bax, and FOXO1 plays an important role in the cytosolic milieu, an inhibition of A/R-induced injury-induced apoptosis may be via the SIRT1-FOXO1 pathway. Therefore, suppression of cell apoptosis might be one of the mechanisms for the protective effects of Cap on the cardiomyocytes given its effects on caspase-3 and Bcl-2 and might be involved with SIRT1. Cells undergoing early apoptosis were defined as the population that was positive for Annexin V but negative for PI. Indeed, in the current study, we have observed using Annexin V/PI double staining and flow cytometer, or TUNEL staining and microscopy, that A/R-induced apoptosis of the rat primary cardiomyocytes was significantly decreased by pretreatment with Cap and sirtinol blocked the effects of Cap. This confirms that the protective effects of Cap on the cardiomyocytes are involved with SIRT1 and through its antiapoptotic role.

5. Conclusions {#sec5}
==============

In summary, the current study has confirmed that Cap could prevent mitochondrial dysfunction and protect the cardiomyocytes against A/R-induced injury and apoptosis via increasing the cell survival rate, decreasing ROS generation, avoiding collapse of the MMP, upregulating antiapoptotic protein Bcl-2, closing mPTP, and decreasing the release of cytochrome c and cleaved caspase-3. The cardioprotective effects of Cap are involved with SIRT1 pathway and at least partly SIRT1 dependent.
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A/R:

:   Anoxia/reoxygenation

Cap:

:   Capsaicin

CPK:

:   Creatine phosphate kinase

DCFH-DA:

:   Dichlorodihydrofluorescein diacetate

FITC:

:   Fluorescein isothiocyanate

I/R:

:   Ischemia/reperfusion

JC-1:

:   5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine

LDH:

:   Lactate dehydrogenase

mPTP:

:   Mitochondrial permeability transition pore

MTS:

:   3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium

PBS:

:   Phosphate-buffered saline

PI:

:   Propidium iodide

ROS:

:   Reactive oxygen species

MMP:

:   Mitochondrial membrane potential.
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Figure S1. Effects of Cap pretreatment with or without coadministration of sirtinol on cell viabilities and LDH and CPK activities in the culture medium after A/R. (a) The cell viabilities did not change using Cap alone (20 *μ*M), sirtinol alone (60 *μ*M), and Cap (20 *μ*M) + sirtinol (60 *μ*M) compared with the control group, as well as using sirtinol (60 *μ*M) + A/R compared with the A/R group. (b) LDH and CPK activities in the culture medium for the cardiomyocytes did not change using Cap alone (20 μM), sirtinol alone (60 *μ*M), and Cap (20 *μ*M) + sirtinol (60 *μ*M) compared with the control group, as well as using sirtinol (60 *μ*M) + A/R compared with the A/R group. Values were expressed as the mean ± SEM (*n* = 6). ^▲▲^*P* \< 0.01 versus the control group. Figure S2. Western blotting bands and graphic presentations of SIRT1 in the neonatal rat primary cardiomyocytes. Compared with the control group, A/R significantly downregulated the expression of SIRT1, regardless of whether with or without sirtinol. Pretreatment with Cap (20 *μ*M) significantly upregulated the expression of SIRT1, regardless of whether using Cap alone or Cap + sirtinol. Values were expressed as the mean ± SEM (*n* = 6). ^▲▲^*P* \< 0.01 versus the control group.

###### 

Click here for additional data file.

![Effects of Cap pretreatment with or without coadministration of sirtinol on cell viabilities and LDH and CPK activities in the culture medium after A/R. (a) A/R caused a significant decrease in cell viabilities, and Cap induced a dose-dependent increase in cell viabilities of the cardiomyocytes decreased by A/R. Coadministration of sirtinol (60 *μ*M) blocked the effects of Cap (20 *μ*M). (b) LDH and CPK activities in the culture medium for the cardiomyocytes were increased in the A/R group compared with the control group. Cap induced a decrease in LDH and CPK activities increased by A/R. Sirtinol blocked the effects of Cap. Values were expressed as the mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus the control group; ^▲▲^*P* \< 0.01 versus the A/R group; ^\#\#^*P* \< 0.01 versus the Cap + A/R group.](OMCL2017-1035702.001){#fig1}

![Western blotting bands and graphic presentations of SIRT1 in the neonatal rat primary cardiomyocytes. The effects of Cap (20 *μ*M) on the expression of SIRT1 after A/R were blocked by coadministration with sirtinol (60 *μ*M). Values were expressed as the mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus the control group; ^▲▲^*P* \< 0.01 versus the A/R group; ^\#\#^*P* \< 0.01 versus the Cap + A/R group.](OMCL2017-1035702.002){#fig2}

![Effects of Cap pretreatment with or without coadministration of sirtinol on ROS generation in the cardiomyocytes induced by A/R. (a) Flow cytometric histogram of DCF fluorescence. (b) Bar graph of cell DCF fluorescence. Values were expressed as the mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus the control group; ^▲▲^*P* \< 0.01 versus A/R group; ^\#\#^*P* \< 0.01 versus the Cap + A/R group.](OMCL2017-1035702.003){#fig3}

![Effects of Cap pretreatment with or without coadministration of sirtinol on the loss of MMP in the cardiomyocytes induced by A/R. (a) Representative flow cytometric dot plots. (b) The histogram of MMP. The ratio of fluorescence in the lower right quadrant and upper right quadrant was used to evaluate the level of MMP. Values were expressed as the mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus the control group; ^▲▲^*P* \< 0.01 versus the A/R group; ^\#\#^*P* \< 0.01 versus the Cap + A/R group.](OMCL2017-1035702.004){#fig4}

![Effects of Cap pretreatment with or without coadministration of sirtinol on the opening of mPTP in the cardiomyocytes induced by A/R. (a) The changes in absorbance at 520 nm during 20 min. (b) The total variation in absorbance at 520 nm in 20 min (ΔOD = *A*~520~ 0 min − *A*~520~ 20 min). Values were expressed as the mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus the control group; ^▲▲^*P* \< 0.01 versus the A/R group; ^\#\#^*P* \< 0.01 versus the Cap + A/R group.](OMCL2017-1035702.005){#fig5}

![Effects of Cap pretreatment with or without coadministration of sirtinol on cytochrome c expression in the rat primary cardiomyocytes after A/R. Western blotting bands (a) and graphic presentations of cytochrome c in both mitochondria (b) and cytosol (c) of the neonatal rat primary cardiomyocytes. A/R induced a significant increase in cytochrome c in cytosol and decrease in cytochrome c in mitochondria. Cap significantly decreased the changes in cytochrome c caused by A/R, and sirtinol significantly blocked the effects of Cap. Values were expressed as the mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus the control group; ^▲▲^*P* \< 0.01 versus the A/R group; ^\#\#^*P* \< 0.01 versus the Cap + A/R group.](OMCL2017-1035702.006){#fig6}

![Effects of Cap pretreatment with or without coadministration of sirtinol on the activities of caspase-3 in the rat primary cardiomyocytes after A/R. A/R induced a significant increase in the activities of caspase-3. Cap significantly decreased the change in the activities of caspase-3 caused by A/R, and sirtinol significantly blocked the effects of Cap. Values were expressed as the mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus the control group; ^▲▲^*P* \< 0.01 versus the A/R group; ^\#\#^*P* \< 0.01 versus the Cap + A/R group.](OMCL2017-1035702.007){#fig7}

![Effects of Cap pretreatment with or without coadministration of sirtinol on caspase-3 and Bcl2 expression in the rat primary cardiomyocytes after A/R. The Western blotting bands and graphic presentations of caspase-3 (a) and Bcl2 in the (b) neonatal rat primary cardiomyocytes, cleaved caspase-3, and Bcl2 protein are shown. A/R induced a significant increase in expression of the cleaved caspase-3 and decrease in expression of the Bcl2 protein. Cap significantly decreased the changes in expression of the cleaved caspase-3 and Bcl2 protein caused by A/R, and sirtinol significantly blocked the effects of Cap. Values were expressed as the mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus the control group; ^▲▲^*P* \< 0.01 versus the A/R group; ^\#\#^*P* \< 0.01 versus the Cap + A/R group.](OMCL2017-1035702.008){#fig8}

![Effects of Cap pretreatment with or without coadministration of sirtinol on the apoptosis of the rat primary cardiomyocytes induced by A/R. (a) Representative flow cytometric dot plots (*x*-axis: Annexin V staining/*y*-axis: PI staining). (b) Quantification of apoptotic cells is shown in (a). Values were expressed as the mean ± SEM (*n* = 6). ^∗∗^*P* \< 0.01 versus the control group; ^▲▲^*P* \< 0.01 versus the A/R group; ^\#\#^*P* \< 0.01 versus the Cap + A/R group.](OMCL2017-1035702.009){#fig9}

![Effects of Cap pretreatment with or without coadministration of sirtinol on the apoptosis of the rat primary cardiomyocytes induced by A/R. Arrows indicate TUNEL-positive (apoptotic) cardiomyocytes. (a) Control group; (b) A/R group; (c) Cap + A/R group; (d) Cap + A/R + sirtinol group.](OMCL2017-1035702.010){#fig10}
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